A brand new research offers reassuring details about the short-term and long-term security of denosumab, a monoclonal antibody that’s used to deal with postmenopausal osteoporosis.
Adverse occasions that had been famous in a pivotal medical trial in women age 60 to 90 years previous handled for three years confirmed no tendency to extend after an extra three years of remedy, the research confirmed.
In addition, women who crossed over from three years of placebo to three years of denosumab skilled no improve in antagonistic results in contrast with women handled for the preliminary three years.
“All of this is consistent with an excellent safety and tolerability profile for denosumab treatment for osteoporosis,” stated Dr. Nelson Watts, lead writer of the research outcomes revealed in Journal of Bone and Mineral Research. The authors famous that, particularly in older women on long-term remedy, many if not all antagonistic occasions might be referred to as “life events” -things that may have occurred whether or not or not the individual was collaborating in a medical trial.
Article: Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension, NB Watts, JP Brown, S Papapoulos, EM Lewiecki, DL Kendler, P Dakin, RB Wagman, A Wang, NS Daizadeh, S Smith, HG Bone, Journal of Bone and Mineral Research, doi: 10.1002/jbmr.3119, revealed on-line 9 March 2017.
Contact our information editors
For any corrections of factual info, or to contact our editorial workforce, please see our contact web page.
Please observe: Any medical info revealed on this web site is just not meant as an alternative to knowledgeable medical recommendation and you shouldn’t take any motion earlier than consulting with a health care skilled. For extra info, please learn our phrases of use.
Copyright Medical News Today: Excluding e mail/sharing providers explicitly provided on this web site, materials revealed on Medical News Today is probably not reproduced, or distributed with out the prior written permission of Medilexicon International Ltd. Please contact us for additional particulars.